Providence Therapeutics announces partnership with University Health Network (UHN) for mRNA therapeutic discovery and development

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Providence Therapeutics Holdings Inc., a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, recently announced its mRNA drug discovery partnership with University Health Network (UHN), ranked first on a list of Canada's top 40 research hospitals by Research Infosource Inc. and within one of the world’s top 5 hospitals for the fourth year in a row, as reported by Newsweek. This collaboration will allow Providence and UHN to develop mRNA-based vaccines and therapeutics for those living with difficult to treat cancers and infectious diseases, using Providence’s proprietary mRNA platform technology.

Arsheen Kaur
Previous

Canadian life sciences on life support? We must stem the innovation brain drain
Next

Cubresa installs first BrainPET Insert System at Lawson Health Research Institute